Skip to main content
Top
Published in: Neurological Sciences 7/2015

01-07-2015 | Original Article

Risk factors and safe dosage of levodopa for wearing-off phenomenon in Chinese patients with Parkinson’s disease

Authors: Huimin Chen, Jinping Fang, Fangfei Li, Liyan Gao, Tao Feng

Published in: Neurological Sciences | Issue 7/2015

Login to get access

Abstract

The objective of this study was to investigate the risk factors of wearing-off phenomenon in Parkinson’s disease (PD) and propose safe dosage of levodopa to reduce wearing-off development based on Chinese cohort. Patients with PD who had taken levodopa (l-dopa) for at least 1 month were recruited. Wearing-off was diagnosed based on validated Chinese version of a patient self-rated 9-question Wearing-Off Questionnaire (WOQ-9) and clinical definition. Eleven variables (gender, disease duration at l-dopa initiation, disease duration at assessment, age at onset, age at assessment, H-Y stage, UPDRS III, l-dopa daily total dosage and dosage adjusted to weight, duration of l-dopa treatment, initial drug recipe) were included in our analysis. Univariate analysis, multivariate logistic regression analysis and decision tree classification model(DTC) were used to detect risk factors of wearing-off. Receiver operating characteristic (ROC) curve and DTC were used to investigate cut-off value of l-dopa to best predict wearing-off. Two hundred and thirty-four patients were investigated in our study, among whom 111 developed wearing-off. Patients with wearing-off tended to receive higher l-dopa dosage and endure longer duration of l-dopa treatment. l-Dopa dosage as 281 mg/day and 4.2 mg/kg/day by ROC, as well as 269 mg/day and 3.2 mg/kg/day by DTC were cut-off values for wearing-off. l-Dopa dosage and duration of l-dopa treatment were related to increased wearing-off development. Cumulative l-dopa dosage and l-dopa daily dosage were better predictive of wearing-off. Inadequate evidence was present for delayed l-dopa initiation. l-Dopa daily dosage no more than 275 mg or 4.2 mg/kg was regarded as safe.
Literature
1.
go back to reference Zhang ZX et al (2005) Parkinson’s disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet 365(9459):595–597PubMedCrossRef Zhang ZX et al (2005) Parkinson’s disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet 365(9459):595–597PubMedCrossRef
2.
go back to reference Poewe W et al (2010) Levodopa in the treatment of Parkinson’s disease: an old drug still going strong. Clin Interv Aging 5:229–238PubMedCentralPubMed Poewe W et al (2010) Levodopa in the treatment of Parkinson’s disease: an old drug still going strong. Clin Interv Aging 5:229–238PubMedCentralPubMed
3.
go back to reference Benbir G et al (2006) A hospital-based study: risk factors in development of motor complications in 555 Parkinson’s patients on levodopa therapy. Clin Neurol Neurosurg 108(8):726–732PubMedCrossRef Benbir G et al (2006) A hospital-based study: risk factors in development of motor complications in 555 Parkinson’s patients on levodopa therapy. Clin Neurol Neurosurg 108(8):726–732PubMedCrossRef
4.
go back to reference Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16(3):448–458PubMedCrossRef Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16(3):448–458PubMedCrossRef
5.
go back to reference Cilia R et al (2014) The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa. Brain 137(Pt 10):2731–2742PubMedCentralPubMedCrossRef Cilia R et al (2014) The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa. Brain 137(Pt 10):2731–2742PubMedCentralPubMedCrossRef
6.
go back to reference Warren Olanow C et al (2013) Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord 28(8):1064–1071PubMedCrossRef Warren Olanow C et al (2013) Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord 28(8):1064–1071PubMedCrossRef
7.
go back to reference Chen W et al (2014) Prevalence of wearing-off and dyskinesia among the patients with Parkinson’s disease on levodopa therapy: a multi-center registry survey in mainland China. Translational Neurodegeneration 3(1):26PubMedCentralPubMedCrossRef Chen W et al (2014) Prevalence of wearing-off and dyskinesia among the patients with Parkinson’s disease on levodopa therapy: a multi-center registry survey in mainland China. Translational Neurodegeneration 3(1):26PubMedCentralPubMedCrossRef
8.
go back to reference Kum WF et al (2009) Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson’s disease. J Clin Neurosci 16(8):1034–1037PubMedCrossRef Kum WF et al (2009) Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson’s disease. J Clin Neurosci 16(8):1034–1037PubMedCrossRef
9.
go back to reference Schrag A, Quinn N (2000) Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study. Brain 123(Pt 11):2297–2305PubMedCrossRef Schrag A, Quinn N (2000) Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study. Brain 123(Pt 11):2297–2305PubMedCrossRef
10.
go back to reference Juri-Claveria C et al (2007) Risk factors associated with the development of motor complications in Parkinson’s disease. A study in a Chilean population. Rev Neurol 45(2):77–80PubMed Juri-Claveria C et al (2007) Risk factors associated with the development of motor complications in Parkinson’s disease. A study in a Chilean population. Rev Neurol 45(2):77–80PubMed
11.
go back to reference Hauser RA, McDermott MP, Messing S (2006) Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 63(12):1756–1760PubMedCrossRef Hauser RA, McDermott MP, Messing S (2006) Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 63(12):1756–1760PubMedCrossRef
12.
go back to reference Kurlan R (2005) “Levodopa phobia”: a new iatrogenic cause of disability in Parkinson disease. Neurology 64(5):923–924PubMedCrossRef Kurlan R (2005) “Levodopa phobia”: a new iatrogenic cause of disability in Parkinson disease. Neurology 64(5):923–924PubMedCrossRef
13.
go back to reference Zhang ZX et al (2014) Chinese culture permeation in the treatment of Parkinson disease: a cross-sectional study in four regions of China. BMC Res Notes 7:65PubMedCentralPubMedCrossRef Zhang ZX et al (2014) Chinese culture permeation in the treatment of Parkinson disease: a cross-sectional study in four regions of China. BMC Res Notes 7:65PubMedCentralPubMedCrossRef
14.
go back to reference Bellazzi R, Zupan B (2008) Predictive data mining in clinical medicine: current issues and guidelines. Int J Med Inform 77(2):81–97PubMedCrossRef Bellazzi R, Zupan B (2008) Predictive data mining in clinical medicine: current issues and guidelines. Int J Med Inform 77(2):81–97PubMedCrossRef
15.
go back to reference Podgorelec V et al (2002) Decision trees: an overview and their use in medicine. J Med Syst 26(5):445–463PubMedCrossRef Podgorelec V et al (2002) Decision trees: an overview and their use in medicine. J Med Syst 26(5):445–463PubMedCrossRef
16.
go back to reference Hughes AJ et al (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184PubMedCentralPubMedCrossRef Hughes AJ et al (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184PubMedCentralPubMedCrossRef
17.
go back to reference Chan A et al (2011) A validation study of the Chinese wearing off questionnaire 9-symptom for Parkinson’s disease. Clin Neurol Neurosurg 113(7):538–540PubMedCrossRef Chan A et al (2011) A validation study of the Chinese wearing off questionnaire 9-symptom for Parkinson’s disease. Clin Neurol Neurosurg 113(7):538–540PubMedCrossRef
18.
go back to reference Stamp LK et al (2012) Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 64(8):2529–2536PubMedCrossRef Stamp LK et al (2012) Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 64(8):2529–2536PubMedCrossRef
19.
go back to reference Gray R et al (2014) Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 384(9949):1196–1205PubMedCrossRef Gray R et al (2014) Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 384(9949):1196–1205PubMedCrossRef
20.
go back to reference de la Fuente-Fernandez R et al (2004) Presynaptic mechanisms of motor fluctuations in Parkinson’s disease: a probabilistic model. Brain 127(Pt 4):888–899PubMedCrossRef de la Fuente-Fernandez R et al (2004) Presynaptic mechanisms of motor fluctuations in Parkinson’s disease: a probabilistic model. Brain 127(Pt 4):888–899PubMedCrossRef
21.
go back to reference Muller T et al (2000) Levodopa in plasma correlates with body weight of parkinsonian patients. Parkinsonism Relat Disord 6(3):171–173PubMedCrossRef Muller T et al (2000) Levodopa in plasma correlates with body weight of parkinsonian patients. Parkinsonism Relat Disord 6(3):171–173PubMedCrossRef
22.
go back to reference de la Fuente-Fernandez R (2013) Imaging of dopamine in PD and implications for motor and neuropsychiatric manifestations of PD. Front Neurol 4:90PubMedCentralPubMed de la Fuente-Fernandez R (2013) Imaging of dopamine in PD and implications for motor and neuropsychiatric manifestations of PD. Front Neurol 4:90PubMedCentralPubMed
23.
go back to reference de la Fuente-Fernandez R et al (2001) Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson’s disease: PET evidence of increased dopamine turnover. Ann Neurol 49(3):298–303PubMedCrossRef de la Fuente-Fernandez R et al (2001) Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson’s disease: PET evidence of increased dopamine turnover. Ann Neurol 49(3):298–303PubMedCrossRef
24.
go back to reference Wu H et al (2014) Catechol-O-methyltransferase Val158Met polymorphism: Modulation of wearing-off susceptibility in a Chinese cohort of Parkinson’s disease. Parkinsonism Relat Disord 20(10):1094–1096PubMedCrossRef Wu H et al (2014) Catechol-O-methyltransferase Val158Met polymorphism: Modulation of wearing-off susceptibility in a Chinese cohort of Parkinson’s disease. Parkinsonism Relat Disord 20(10):1094–1096PubMedCrossRef
25.
go back to reference Hao H et al (2014) Association of Catechol-O-Methyltransferase and monoamine oxidase B gene polymorphisms with motor complications in parkinson’s disease in a Chinese population. Parkinsonism Relat Disord 20(10):1041–1045PubMedCrossRef Hao H et al (2014) Association of Catechol-O-Methyltransferase and monoamine oxidase B gene polymorphisms with motor complications in parkinson’s disease in a Chinese population. Parkinsonism Relat Disord 20(10):1041–1045PubMedCrossRef
Metadata
Title
Risk factors and safe dosage of levodopa for wearing-off phenomenon in Chinese patients with Parkinson’s disease
Authors
Huimin Chen
Jinping Fang
Fangfei Li
Liyan Gao
Tao Feng
Publication date
01-07-2015
Publisher
Springer Milan
Published in
Neurological Sciences / Issue 7/2015
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-015-2078-4

Other articles of this Issue 7/2015

Neurological Sciences 7/2015 Go to the issue